Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Watch

ERK5 Is a Potential Therapeutic Target in ALK-Positive Neuroblastoma

DOI: 10.1158/2159-8290.CD-RW2014-229 Published December 2014
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: ERK5 promotes ALK-induced transcription of MYCN and enhances neuroblastoma cell proliferation.

  • Mechanism: ALK-driven activation of ERK5 via PI3K/AKT and MEKK3 is required for MYCN transcription.

  • Impact: ERK5 blockade may enhance the efficacy of the ALK inhibitor crizotinib in ALK-positive neuroblastoma.

Anaplastic lymphoma kinase (ALK) has been implicated as an oncogenic driver in pediatric neuroblastoma and is frequently activated by amplification and gain-of-function mutations. However, results from phase I trials have suggested that, in contrast to other tumor types such as non–small cell lung cancer, single-agent therapy with the ALK inhibitor crizotinib is not effective in pediatric patients with ALK-positive neuroblastoma, underscoring the need to identify additional therapeutic targets. Umapathy and colleagues found that ALK stimulated phosphorylation of the kinase ERK5 (also known as MAPK7) in ALK-positive neuroblastoma cell lines and that ERK5 activation was necessary for ALK-induced transcription of the oncogene MYCN, which is commonly amplified in neuroblastoma and is associated with poor prognosis. ALK-driven activation of ERK5 was mediated by PI3K–AKT signaling and downstream phosphorylation of the ERK5 activator MEKK3 (also known as MAP3K3), and treatment with crizotinib or PI3K pathway inhibitors diminished the levels of phosphorylated ERK5 in the nucleus and reduced NMYC expression in neuroblastoma cells. Single-agent treatment with the ERK5 inhibitor XMD8-92 impaired the proliferation of ALK-positive, MYCN-amplified neuroblastoma cell lines in vitro, indicating that ERK5 may be a potential therapeutic target. Furthermore, combined treatment with crizotinib and XMD8-92 synergistically decreased neuroblastoma cell growth, suggesting that ERK5 blockade may enhance the efficacy of crizotinib in ALK-positive neuroblastoma. Consistent with this idea, dual inhibition of ALK and ERK5 more effectively inhibited the growth of ALK-positive xenograft tumors in vivo compared with single-agent treatment and resulted in reduced expression of NMYC in tumors. These findings suggest that concomitant ALK and ERK5 inhibition may represent an effective therapeutic strategy to suppress oncogenic MYCN expression and potentially overcome crizotinib resistance in patients with ALK-positive neuroblastoma.

Umapathy G, El Wakil A, Witek B, Chesler L, Danielson L, Deng X, et al. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Sci Signal 2014;7:ra102.

Notes

Note: Research Watch is written by Cancer Discovery Science Writers. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

  • ©2014 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 4 (12)
December 2014
Volume 4, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
ERK5 Is a Potential Therapeutic Target in ALK-Positive Neuroblastoma
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
ERK5 Is a Potential Therapeutic Target in ALK-Positive Neuroblastoma
Cancer Discov December 1 2014 (4) (12) 1363; DOI: 10.1158/2159-8290.CD-RW2014-229

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
ERK5 Is a Potential Therapeutic Target in ALK-Positive Neuroblastoma
Cancer Discov December 1 2014 (4) (12) 1363; DOI: 10.1158/2159-8290.CD-RW2014-229
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Epstein–Barr Virus–Induced Antitumor Immune Response May Be Harnessable
  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
Show more Research Watch

Neuroblastoma

  • Resistance to ALK Inhibitors in Neuroblastoma Is Regulated by BORIS
  • MYCN Amplification Promotes Enhancer Invasion in Neuroblastoma
  • SEMA3C Depletion Promotes Neuroblastoma Metastatic Dissemination
Show more Neuroblastoma
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement